CG Oncology, Inc.
CGONHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeCG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company carries a $6.34B market cap, placing it firmly in the mid-cap category. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Market Cap
$6.34B
Beta
0.22
P/E (TTM)
—
P/E (Fwd)
-25.85
EPS (TTM)
$-2.42
EPS (Fwd)
$-2.78
ROE
-20.8%
ROA
-14.4%
Cash
$1.08B
Total Debt
$7.6M
Free CF
-$105.9M
52W Change
168.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $1.08B in cash comfortably exceeding the $7.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$105.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -20.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $191K (2022) to $4.0M (2025), reflecting a 2015% increase over the period.
With a beta below 0.7, CG Oncology, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, CGON has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for CG Oncology, Inc. and its sector.